drugset / Trial / NCT04190823
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability and pharmacokinetics of RC98 for injeciton in subjects with advanced malignant solid tumors.
Timeline
- Start
- 2020-03-15
- Primary completion
- 2023-12-28
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC98 | Monoclonal antibody | 0.003 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 0.03 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 2.5 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 5 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 10 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 15 mg/kg | — |
| Subject | RC98 | Monoclonal antibody | 20 mg/kg | — |